Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications.

Abstract

The 5-HT(2C) receptor subtype has been implicated in a wide variety of conditions including obesity, anxiety, depression, obsessive compulsive disorder, schizophrenia, migraine and erectile dysfunction and as a consequence has received considerable attention as a target for drug discovery. Here we review the pharmacological, pharmacokinetic and toxicological profile of WAY-163909 {(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole}, a novel 5-HT(2C) receptor selective agonist. Consistent with a potential therapeutic utility in obesity, schizophrenia and depression WAY-163909 was found to have robust dose-dependent effects in animal models of obesity, psychotic-like behavior or depression.

• Authors: John Dunlop, Karen L Marquis, H K Lim, Louis Leung, John Kao, Cynthia Cheesman, Sharon Rosenzweig-Lipson
• Journal: CNS drug reviews (CNS Drug Rev) 2006 Fall-Winter Vol. 12 Issue 3-4 Pg. 167-77 ISSN: 1080-563X [Print] United States
• PMID: 17227285 (Publication Type: Evaluation Study, Journal Article, Review)

Chemical References

• 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta(b)(1,4)diazepino(6,7,1hj)indole
• Antidepressive Agents
• Antipsychotic Agents
• Azepines
• Indoles
• Serotonin 5-HT2 Receptor Agonists

Topics

• Animals
• Antidepressive Agents (pharmacology, therapeutic use)
• Antipsychotic Agents (chemistry, pharmacology, therapeutic use)
• Azepines (chemistry, metabolism, pharmacology, therapeutic use)
• Eating (drug effects)
• Humans
• Indoles (chemistry, metabolism, pharmacology, therapeutic use)
• Serotonin 5-HT2 Receptor Agonists